Ingredient or product comparison
Is GHK-Cu Cosmetic FDA Approved Status: Regulatory Comparison
Understanding the GHK-Cu Cosmetic FDA approved status requires comparing it against other regulatory pathways and peptide classifications. The table below outlines the key distinctions between cosmetic-grade GHK-Cu, research-grade peptides, and FDA-approved ph
This source-based comparison does not add ratings or recommend a winner.
- Understanding the GHK-Cu Cosmetic FDA approved status requires comparing it against other regulatory pathways and peptide classifications. The table below outlines the key distinctions between cosmetic-grade GHK-Cu, research-grade peptides, and FDA-approved pharmaceutical peptides.
- GHK-Cu Cosmetic Ingredient
- No. Post-market enforcement only
- Cosmetic (21 CFR 700)
- Yes. Copper Tripeptide-1
- Topical skincare formulations with appearance claims
- GHK CU Cosmetic 5MG
- Safe for cosmetic use under intended conditions; no drug claims permitted
- Research-Grade Peptide
- No. Not intended for human use
- Laboratory reagent
- Not applicable
- Biological research, mechanism studies, in vitro experiments
- GHK CU Copper Peptide
- Held to higher purity standards than cosmetic-grade; sequencing verified
- FDA-Approved Drug Peptide
- Yes. New Drug Application (NDA) or Biologics License Application (BLA)
- Pharmaceutical (21 CFR 314)
- Treatment of disease or alteration of bodily function
- Insulin, exenatide, liraglutide
- Requires Phase I-III clinical trials, manufacturing under cGMP, post-market surveillance
- Compounded Peptide (503B)
- No. Compounded under state pharmacy law or FDA 503B oversight
- Compounding pharmacy
- Custom formulations for individual patients
- Compounded semaglutide, tirzepatide
- Not FDA-approved as finished drug product; active ingredient may be FDA-approved molecule
- Dietary Supplement Peptide
- No. DSHEA regulatory framework
- Dietary supplement (21 USC 321)
- Oral ingestion with structure/function claims only
- Collagen peptides, amino acid blends
- Cannot make disease claims; FDA enforces adulteration and misbranding post-market